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Single-gene mutations can produce human progeroid
syndromes—phenotypes that mimic usual or “norma-
tive” aging. These can be divided into two classes—
those that have their impacts upon multiple organs
and tissues (segmental progeroid syndromes) and
those that have their major impacts upon a single or-
gan or tissue (unimodal progeroid syndromes). The
prototypic example of the former is the Werner syn-
drome, a condition caused by mutations of the RecQ
family of DNA helicases. Research on the Werner syn-
drome and a surprising number of other progeroid
syndromes support the importance of the mainte-
nance of genomic stability as a partial antidote to
aging. The prototypic examples of the latter are Alz-
heimer type dementias. The three gene products that
cause rare autosomal-dominant early-onset varieties
of these disorders all participate in the modulation of
the  amyloid precursor protein. They thus support
the importance of the maintenance of proper protein
processing and folding as a partial antidote to aging.
Special Opportunities and Special Difficulties
of Research on Aging in Our Species
More is known about the range of variation of the anat-
omy, physiology, biochemistry, nutrition, microbiology,
immunology, pathology, pharmacology, behavior, and
demography of Homo sapiens than any other animal
species on earth. Until about the last decade or so, the
missing ingredient was the formal genetic analysis of
our species, including a comprehensive catalog of al-
lelic variants. Progress in that direction has been spec-
tacular, providing unprecedented opportunities for the
detailed biochemical genetic characterizations of in-
dividuals with unusually well-preserved or unusually
fragile functions during the life course. Moreover, given
our propensity to colonize virtually every segment of
the globe there are almost unlimited opportunities to
uncover novel nature-nature interactions.
This review focuses upon rare mutations that appear
to accelerate the ages of onset and/or the rates of pro-
gression of degenerative and proliferative disorders
that mimic, with varying degrees of fidelity, what the
physician and pathologist would characterize as senes-
cent phenotypes. Every gerontologist would agree that
a much more informative approach would be to focus
upon the genetic basis of unusually well-preserved
structure and function. There are many ways to damage
a machine, most of them probably differing from what
drives aging as it unfolds in most individuals. There are
comparatively few ways, however, to make the machine*Correspondence: gmmartin@u.washington.eduwork better for longer periods of time. Although there
have been some recent attempts to uncover alleles as-
sociated with unusual longevities (Barzilai et al., 2003),
progress has been limited by a paucity of data on rates
of change in a wide range of physiological functions
using highly sensitive and relatively noninvasive meth-
ods that are amenable to longitudinal studies in very
large populations of middle-aged subjects (Martin,
2002a). Given such data, genetic methods such as sib-
pair analysis (Szatkiewicz and Feingold, 2004) have the
potential to uncover subsets of alleles that modulate
aging as it usually unfolds, at least for those pheno-
types that are not modulated by hundreds of alleles
with very small effects. But this is a review that must
await a decade or more of progress. Meanwhile we
have to make the most of what we can from reports
of deleterious mutations. Fortunately, there is a strong
rationale for this approach—namely that for every allele
that codes for a defective protein or suboptimum regu-
lation, there can exist, in principle, alleles with functions
superior to those of wild-type, including alleles that
provide enhanced functions late in the life course. This
is predicted by the evolutionary theory of aging, as
“good” alleles as well as “bad” alleles can escape the
force of natural selection (Martin, 2002b). In short, the
discovery of genes that lead to unsuccessful aging can
lead us to the discovery of variants that can lead to
unusually successful aging.
Segmental and Unimodal Progeroid Syndromes
It is convenient to classify genetic syndromes that
mimic senescent features into two broad categories—
those that impact upon a suite of such features involv-
ing a number of organ systems and tissues and those
that have a predominant impact only upon a single or-
gan system or tissue. I have referred to the former as
“segmental progeroid syndromes” (Martin, 1978) and
the latter as “unimodal progeroid syndromes” (Martin,
1982). In this review, we shall focus upon those entities
for which a single gene or genes have been identified
as the underlying primary event. Not all of these are
reviewed, given the potentially very large number of
these disorders and the lack of more precise informa-
tion on the degrees of concordance and discordance
with senescent phenotypes as they usually occur in the
general population. Given the fact that we are still
largely ignorant of the range of mechanisms responsi-
ble for senescent phenotypes as they usually unfold in
different individuals, it is prudent to use the term “pro-
geroid syndrome” rather than “premature aging syn-
drome.” The suffix “-oid” means “like.” It does not imply
that the phenotypes or their underlying mechanisms
exactly duplicate usual or “normative” aging. The latter
themselves are likely to be mechanistically hetero-
geneous. This author embraces the evolutionary theory
of aging, which does not predict determinative, se-
quential changes in gene action that lead to highly re-
producible phenotypes. (Indeed, every physician will
note that patterns of aging are highly variable among
Cell
524geriatric patients.) While the discovery of a “public t
tmechanism of aging” in C. elegans, Drosophila melano-
mgaster, and Mus musculus domesticus is of great im-
aportance (Partridge and Gems, 2002), the leaky muta-
ntions that formed the basis for these discoveries can
ube interpreted as reporting on genetic pathways that
hevolved to maintain a high degree of somatic main-
Ctenance under harsh environmental conditions that
htrigger transient withdrawal from the business of repro-
Dduction. There are numerous examples of such “dia-
cpauses” in nature, particularly in insects (Brown and
gHodek, 1983); caloric restriction may well be another
rdiapausal mechanism that evolved within numerous
1phyla. These mechanisms of survival are eventually
dtrumped by a variety of gene actions that escape the
iforce of natural selection (Martin, 2002b).
m
aExamples of Segmental Progeroid Syndromes
tThe Werner Syndrome-Homozygous or Compound
oHeterozygous Null Mutations at the RecQL2
n(RecQ3) (WRN) Locus
oThis is the prototypic segmental progeroid syndrome
Gbecause it impacts upon a very large number of senes-
ccent phenotypes of major medical importance (Goto et
kal., 2001). In typical cases there is no clinical evidence
gof an abnormality until puberty, when the affected sub-
tject fails to demonstrate an adolescent growth spurt.
wThe result is short stature as an adult (but not as a
jschoolchild). Other features (see Figure 1) include bilat-
teral ocular cataracts; a characteristic set of dermato-
alogical signs (atrophic, “tight” skin, reminiscent of scle-
oroderma, pigmentary abnormalities, premature graying
land/or thinning of scalp hair, striking loss of peripheral
subcutaneous tissue, skin ulcerations [including virtu-
dally pathognomonic ulcerations around the malleoli and
t
Achilles tendons], subcutaneous and peri-articular de-
t
posits of calcium [Leone et al., 2005], and a “bird-like,”
b
“pinched” facie); osteoporosis (particularly of the long
m
bones of the legs); radiologically characteristic osteo- b
sclerosis of the distal phalanges; hypogonadism; sev- d
eral types of arteriosclerosis; a history of myocardial f
infarction and, less frequently, the effects of cerebral c
ischemia; severe calcifications of heart valves; variable t
evidence of type 2 diabetes mellitus; peripheral neurop- w
athy; benign and malignant neoplasia, predominately of t
nonepithelial origins and including high frequencies of (
rare cancers (Goto et al., 1996). Multiple distinct pri-
mary neoplasms can occur—as many as five malignan- a
cies in one patient (Tsuchiya et al., 1991). The two major B
causes of death (at a median age of around 47–48 a
years) are myocardial infarctions and cancer. A family s
history frequently reveals parental consanguinity, as m
one would expect for a rare autosomal recessive condi- i
tion. Experienced geriatricians will note a number of im- t
portant discordances between the above phenotype t
and what is typically observed in “normative” aging— o
for example, the pattern of neoplasms and the distribu- p
tion of the osteoporosis. a
Early work with cultured somatic cells from Werner t
patients documented accelerated clonal senescence, a r
mosaic of chromosomal translocations, deletions, and g
inversions, and elevated frequencies of somatic muta- v
ttions, particularly deletions. Positional cloning led tohe identification of the mutant locus as a member of
he RecQ family of helicases. Affected patients are ho-
ozygous or doubly heterozygous for null mutations
ssociated with truncated gene products missing their
uclear localization signals. The WRN helicase is un-
sual in that it is the only one of five members of the
uman family that includes an exonuclease domain.
laims have been made for the functioning of the WRN
elicase in a variety of DNA transactions, including
NA replication (Sharma et al., 2004), homologous re-
ombination (Monnat and Saintigny, 2004), nonhomolo-
ous end joining (Oshima et al., 2002), base excision
epair (Ahn et al., 2004), and transcription (Balajee et al.,
999). It is likely to have a role in a number of pathways
ealing with the resolution of unusual DNA substrates,
ncluding, probably of considerable importance, telo-
ere sequences. The latter assertion is supported by
t least four lines of evidence. The first is the fact that
ransfection of Werner cells with the catalytic subunit
f telomerase bypasses the premature replicative se-
escence (Wyllie et al., 2000). The second is the ability
f trisubstituted acridine ligands that interact with
-quadriplex DNA structures to inhibit the Werner heli-
ase (Li et al., 2001). The third is the observation that a
nockout of telomerase function in mice, after several
enerations of breeding, reduces the unusually long
elomere murine sequences to sizes characteristic of
hat is observed in the somatic cells of human sub-
ects. Such “humanization” revealed a variety of pheno-
ypes characteristic of the Werner syndrome (Chang et
l., 2004; Du et al., 2004). The fourth and most recent
bservation is a role for the Werner helicase in telomere
agging strand synthesis (Crabbe et al., 2004).
Approximately 10% of cases of apparent Werner syn-
rome have somewhat atypical clinical features and fail
o reveal mutations at the WRN locus or deficiencies in
he WRN protein. A few of these cases were shown to
e due to mutations at the LMNA/C locus, but at do-
ains upstream from the common mutation responsi-
le for the classical form of the Hutchinson-Gilford syn-
rome (see below) (Chen et al., 2003). Candidate genes
or other forms of “Atypical Werner Syndrome” would
ertainly include the growing list of proteins that in-
eract with the Werner helicase; of particular interest
ould be members of the complex of proteins that par-
icipate in the resolution of stalled DNA replication forks
Robison et al., 2004).
Research on the detailed molecular biology of gene
ctions at WRN and other RecQ loci (notably at the
LM locus, mutations at which are associated with an
rray of neoplasms quite comparable with what is ob-
erved in usual aging) is at a stage of rapid develop-
ent. We would especially like to know the potential
mpacts of more subtle deficiencies of these gene ac-
ions, including those related to the numerous proteins
hat interact with these helicases to make these marvel-
us “molecular motors.” Only a few papers have ap-
eared concerning the impact of WRN polymorphisms
nd WRN haploinsufficiency upon senescent pheno-
ypes and life span; the data remain insufficient to war-
ant any definitive conclusions. This is unfortunate,
iven the possibility that these much more prevalent
ariants could impact upon substantially larger popula-
ions. The Werner syndrome has already helped to clar-
Review
525Figure 1. Photographs of a Female Patient with the Werner Syndrome, the Prototypic Segmental Progeroid Syndrome
The patient had multiple cardinal signs of the classical form of the disease, including bilateral cataracts, characteristic dermatological pathol-
ogy, short stature, premature graying and thinning of scalp hair, and parental consanguinity (she was the product of a second cousin marriage).
She also had type 2 diabetes mellitus, hypogonadism (with menopause at age 35 years), osteoporosis, flat feet, and a characteristic high-
pitched, squeaky voice. Cytogenetic studies revealed minor mosaicisms for autosomal translocations, deletions, and aneuploidy involving
the X chromosome, initially raising the question of a mosaic Turner syndrome (Jaramillo et al., 1985), but consistent with the more general
cytogenetic instability and cell selection reported in such patients (Salk et al., 1981a, 1981b). The patient died at the age of 61 of unreported
causes. The International Registry of Werner Syndrome (http://www.pathology.washington.edu/research/werner/registry/frame2.html) deter-
mined that this patient was homozygous for a previously described large genomic deletion involving exons 19–23 of the WRN gene. (A) Age
w13 (growth had ceased at age 12); (B) Age 21; (C) Age 56. Photographs are courtesy of the patient’s spouse, with informed consent of
the patient.ify some important issues in biogerontology, however.
First, it provides strong support for the notion that ge-
nomic instability is important for a variety of senescent
phenotypes. This is reinforced by studies of other puta-
tive progeroid syndromes. Second, it supports the propo-
sition that replicative senescence contributes to various
senescent phenotypes. Third, it supports the proposi-
tion that mesenchymal tissues play major roles in the
modulation of senescent phenotypes since mesenchy-
mal cell types appear to be especially vulnerable
targets and are disproportionately represented in the
spectrum of neoplasms observed in that disorder.
Fourth, it raises the question that DNA crosslinking
agents may have progeroid effects, as somatic cells
from Werner patients appear to be particularly suscep-
tible to drugs that induce DNA interstrand crosslinks
(Poot et al., 2001).
Classical Hutchinson-Gilford Progeria Syndrome—
Dominant mutations at the Lamin A/C Locus
(G608G Splicing Mutation)
The old literature referred to this exceedingly rare con-
dition (w1/8 million births) as “Childhood Progeria” in
order to differentiate it from the Werner syndrome,
which is sometimes referred to as “Adult Progeria.” A
skilled pediatrician can make the diagnosis within the
first few months of life and certainly by the end of the
first year of life (DeBusk, 1972; Brown, 2003). The disor-der thus clearly impacts upon normal development and
thus one can question the appropriateness of the des-
ignation as a Progeria (literally, “premature aging”). Its
striking features include severe retardation of growth
and marked loss of subcutaneous fat, particularly of
the face and limbs, giving the characteristic “bird-like”
facies and the facile mapping of the veins of the scalp.
Skin appendages disappear, including eye lashes and
eyebrows. Like the Werner syndrome, the voice is
weak, high pitched, or squeaky. Clavicles may consist
only of connective tissue, without developed cartilage.
The connective tissue abnormalities can lead to dislo-
cated hips and the characteristic “horse-riding” stance;
the result can be a form of osteoarthritis. Like Werner
syndrome patients, abnormalities of the distal phalan-
ges are seen by X-ray. Also like the Werner syndrome,
there is no evidence of any cognitive impairment in the
absence of any complications of arteriosclerosis. The
latter, particularly atherosclerosis, is the most compel-
ling feature from the point of view of the gerontologist,
many of whom would regard it as a characteristic fea-
ture of aging in our species, although with substantial
variations in rates of development as functions of the
background genome and the environment (Eggen and
Solberg, 1968). Atherosclerosis is certainly an example
of a phenotype that almost always escapes the force
of natural selection in human populations and therefore
Cell
526might reasonably be regarded as a senescent pheno- p
wtype. For Hutchinson-Gilford patients, however, it may
result in myocardial infarction and death at around the t
Mage of 13; such virulent mutations are therefore under
strong selective pressure. The histology of atheroscler- s
aotic arteries require much more study, but the evidence
suggests only subtle differences from the type of ath- t
terosclerosis one observes in the population at large;
one study suggested that the arteries are more suscep- s
etible to mechanical damage (Stehbens et al., 1999)—a
prescient observation, considering the subsequent elu- a
Acidation of the nature of the abnormal gene products.
Those gene products turned out to be structural com- s
gponents of the nuclear membrane (Lamins A and C)
(Goldman et al., 2004). About 90% of the classical cases t
mso far investigated result from dominant de novo germ-
line mutations involving a C to T transition (Eriksson et 2
ral., 2003). The new codon continues to code for glycine
but results in a splicing abnormality such that an abnor- n
tmal lamin A is synthesized that is missing 50 amino
acids near the C-terminal end of the molecule (Eriksson n
set al., 2003). Nuclear lamins are members of a family
of intermediate filament proteins. Lamins A and C are p
among at least four gene products derived from the sin-
gle lamin A/C locus via differential splicing. They have o
tmultiple roles, still poorly defined, associated with their
localizations on the inner nuclear envelope and as a c
lfibrillar web throughout the nucleoplasm. These can be
presumed to include nuclear structural and regulatory m
Minteractions with chromatin. Tissues undergoing me-
chanical stresses are particularly vulnerable to lamin E
CA/C mutations (Worman and Courvalin, 2004). The Hutch-
inson-Gilford syndrome may therefore influence re- T
isearch on the pathogenesis of atherosclerosis as it
usually occurs. Perhaps the primary lesion is a reaction f
pof smooth muscle and/or endothelial cells to arterial
injury such as those associated with hypertension or l
dwith alterations in blood flow at arterial bifurcations. In-
flammatory responses, including infiltrations by macro- o
aphages and depositions of cholesterol and oxidized li-
poproteins, might therefore be downstream processes. b
cIt is also possible that accelerated clonal, replicative
senescence of cells of the vascular wall sets the stage e
ffor the subsequent atherosclerotic events, not only in
the Werner and Hutchinson-Gilford syndromes, but r
pperhaps also in most forms of atherosclerosis (Martin
and Sprague, 1972). t
sAtaxia Telangiectasia (ATM)
Patients affected by this autosomal recessive disorder R
Texhibit progressive cerebellar degeneration, particu-
larly of Purkinje cells, a spectrum of immunodeficiency G
Mmarkers with resulting susceptibility to infections (es-
pecially otitis media, sinusitis, and bronchopneumonia), (
Ihypogonadism, a variety of degenerative and prolifera-
tive lesions of the skin and skin appendages (telangiec- H
dtasia, atrophy, pigmentary abnormalities, graying of
hair, senile keratosis), and a wide range of malignant a
ineoplasms, with non-Hodgkin’s lymphomas being par-
ticularly frequent (reviewed by Meys, 2003). These pa- o
mtients are hypersensitive to ionizing irradiation, so that
radiation treatment for neoplasia is problematic. a
aAffected patients are homozygous or doubly hetero-
zygous for a range of mutations leading to a deficiency h
iof an unusually large protein kinase that is at a nodalosition in a signaling cascade that comes into play
hen there are double-strand breaks in DNA, such as
hose produced by ionizing radiation (reviewed by
cKinnon, 2004). These include physiological double-
trand breaks such as those that occur during meiosis
nd during recombination associated with the matura-
ion of the immune system, thus explaining features of
he pathology. There is evidence that the kinase is re-
ponding to endogenous oxidative stress (Reichenbach
t al., 2002). The insulin-like growth factor-1 receptor is
mong the downstream target genes regulated by the
TM kinase (Shahrabani-Gargir et al., 2004). This
hould be of considerable interest to gerontologists,
iven the evidence that the IGF-1 pathway has been
he first metabolic network implicated as a “public”
odulation of rates of aging (Partridge and Gems,
002). In the presence of DNA damage, ATM directly
egulates CREB, a transcription factor important for
euronal homeostasis and survival (Shi et al., 2004);
his may provide an important clue for the basis of the
eurodegenerative phenotypes, although the unusual
usceptibility of the cerebellar cortex will have to be ex-
lained.
Neurologists have long noted a remarkable variability
f age of onset of the cerebellar degenerative signs of
he disease, often leading to considerable uncertainty
oncerning the diagnosis. We now know that unusually
ate onset of the disorder can be explained by leaky
utations (Dork et al., 2004; Sutton et al., 2004).
yotonic Dystrophy (DM1-Dominant CTG
xpansions at the DMPK Locus; DM2-Dominant
CTG Expansions at the ZNF9 Locus)
he lesson a gerontologist takes from these disorders
s that gain-of-function nontranslated RNA transcripts
rom a locus with expanded simple repeat units can
roduce transdominant splicing abnormalities at other
oci, resulting in numerous degenerative adult-onset
isorders (e.g., muscle weakness and atrophy, bilateral
cular cataracts, type 2 diabetes mellitus, cardiomyop-
thy, testicular atrophy, immune deficiency) (reviewed
y Ranum and Day, 2004). Although DM1 can be asso-
iated with neuropsychiatric abnormalities and may be
xpressed much earlier, all other clinical features are
ound in both forms of the disease, even though the
epeat units and the genetic loci are distinct. (The ex-
anded DM1 triplet repeat is on chromosome 19 while
he CCTG repeat is in a zing finger gene on chromo-
ome 3.) The common denominator is a novel type of
NA-mediated pathogenesis.
he Berardinelli-Seip Syndrome—Congenital
eneralized Lipodystrophy Type 1 (Recessive
utations at BSCL1) (AGPAT2) and Type 2
Recessive Mutations at BSCL2) (Seipin Locus)
n contrast to what is observed in the Werner and
utchinson-Gilford syndromes, children with this rare
isorder exhibit remarkable accelerations of growth
nd development during the first decade of life, includ-
ng accelerated bone growth and skeletal muscle devel-
pment, clitoromegaly in females, premature develop-
ent of the phallus in males, hirsutism, hyperhidrosis,
nd acanthosis nigrans. These symptoms are associ-
ted with a voracious appetite. There is “a price to pay,”
owever, as they go on to develop increasing levels of
nsulin resistance and diabetes mellitus, hypertriglyceri-
Review
527demia, hypertrophic cardiomyopathy (sometimes asso-
ciated with anginal symptoms), nephropathies (Javor et
al., 2004), premature menopause, lytic lesions of bone,
fatty infiltration of liver (which can lead to cirrhosis),
and, in the type 2 form, CNS symptoms of unknown
neuropathology interpreted as mild mental retardation
but which may well be a neurodegenerative condition.
There is virtually no detectible mature adipose tissue at
birth, although depots thought to provide mainly me-
chanical support (e.g., periorbital fat) as opposed to
major metabolic functions appear to be well preserved
in the type 1 form of the disease. Not surprisingly, se-
rum leptin levels are very low. A variety of other adipo-
kines are also likely to be substantially diminished,
given the paucity of differentiated adipocytes. (For re-
views, see Agarwal et al., 2003 and Agarwal and Garg,
2004.)
The deficient protein responsible for type 1 congeni-
tal generalized lipodystrophy is 1-acylglycerol-3-phos-
phate O-acyltransferase, an enzyme that is highly ex-
pressed in differentiated adipocytes. It catalyzes the
acylation of lysophosphatitic acid to phosphatidic acid
and thus impacts upon the synthesis of tracylglycerol
and glycerophospholipids. The deficient protein in the
type 2 disease is Seipin, named in honor of Martin Seip,
the Norwegian pediatrician who investigated the disor-
der for many decades (Seip and Trygstad, 1963). Seipin
is a novel transmembrane protein localized to the endo-
plasmic reticulum of adipose tissue, brain, and neurons
(so far best documented in motor neurons) (Agarwal
and Garg, 2004). It has some homology to Midasin, a
nuclear protein with an ATPase domain that may func-
tion as a nuclear chaperone (Garbarino and Gibbons,
2002).
The detailed pathogenetic mechanisms of both types
of lipodystrophies remain to be determined. The lesson
for gerontologists, however, is clear—namely that met-
abolic abnormalities of adipocytes can have profound
systemic degenerative effects that may accumulate
during the life course.
Other Segmental Progeroid Syndromes
There are numerous other syndromes characterized by
proliferative and/or degenerative progeroid features as-
sociated with constitutional mutations in single genes.
Examples include many disorders that, like the Werner
syndrome, are associated with various degrees of ge-
nomic instability, such as the Bloom syndrome, the
Rothmund-Thomson syndrome, the Cockayne syn-
drome, trichothiodystrophy, forms of xeroderma pig-
mentosum, the Nijmegen Breakage syndrome, Dysker-
atosis Congenita, and Fanconi Anemia (Digweed and
Sperling, 2004; Hoehn et al., 2003; Hu and Ellis, 2004;
Kitao et al., 2003; Lehmann, 2003; Wu and Hickson,
2003). An example of a segmental progeroid syndrome
that does not have a primary impact upon nuclear ge-
nomic instability, in addition to those noted above
(Myotonic dystrophy and the Berardinelli-Seip syn-
drome), is “Maturity Onset Diabetes of the Young” (type
2). Diabetes, as it usually occurs, is a complex, pleiotro-
pic disorder with impacts upon multiple body systems,
including debilitating late-onset degenerative cardio-
vascular, renal, and visual disorders. Mutations at the
MODY1 locus have been shown to affect hepatocyte
nuclear factor 4 α, a component of a complex transcrip-tional network that acts in liver and in pancreatic β cells
and is involved in the transport of glucose and lipids
(Oxombre et al., 2004).
Examples of Unimodal Progeroid Syndromes
Familial Alzheimer Disease—Three Monogenic Loci:
APP, PS1, PS2
By far the greatest risk factor for the development of
dementias of the Alzheimer type (DAT) is aging; numer-
ous studies have documented exponential rises in the
common “late-onset” forms of the disease. Some have
argued that such neurodegeneration is a disease, not
aging; the former is characterized more by frontal-stria-
tal functional declines while the latter is characterized
more by pathology affecting the medial temporal lobe
and associated cortical networks (Buckner, 2004).
Given evidence that up to w50% of all community-
dwelling subjects over the age of 85 years may have
DAT (Evans et al., 1989), however, one can reasonably
conclude that DAT pathology is part and parcel of aging
in our species. This is certainly correct if one defines
senescent phenotypes as broadly as I have done (i.e.,
phenotypes that escaped the force of natural se-
lection).
Three monogenic forms of familial “early-onset”
forms of DAT have been exceedingly well documented
(reviewed by Bertram and Tanzi, 2004; St George-Hys-
lop et al., 2000). (“Early-onset” is usually arbitrarily de-
fined as cases that manifest before the age of 60—gen-
erally within the fifth and sixth decades, although there
are exceptions within individual pedigrees.) All three
classes of pedigrees involve autosomal dominant mu-
tations. The first to be discovered was a class with
point mutations at the locus coding for the β amyloid
precursor protein on the long arm of chromosome 21,
an early candidate region because of the essentially
complete penetrance of DAT pathology in middle-aged
patients with the Down syndrome (trisomy 21). These
mutations cluster around cleavage sites that modulate
the posttranslational processing of various isoforms of
the β amyloid precursor protein, including the synthesis
of long (Abeta 1–42) and short (Abeta 1–40) derivatives.
These small polypeptides appear to have both physio-
logical and pathological actions, the latter in the form
of neurotoxic moieties, including candidates such as
intracellular dimers, oligomers, and proto-fibrils, and
extracellular aggregates of β amyloid. The discovery of
APP mutations as the basis of a monogenic form of the
disease has driven the entire field of DAT research.
While such emphasis might not be justified on the basis
of the comparatively small number of familial DAT pedi-
grees with APP mutations, the discovery of additional
pedigrees with early-onset familial DAT mutations at
the presenilin 1 and 2 loci has highlighted an entire net-
work of interacting proteins engaged in such functions
as the regulation of transcription and cytoskeletal re-
modeling (Figure 2). This network includes APOE, the
only genetic locus so far firmly established as a strong
risk factor for the “garden variety” late-onset common
forms of DAT. Three common polymorphic alleles of
APOE have been documented to differentially impact
upon risk in numerous populations around the world,
the epsilon 4 allele having uniformly detrimental effects.
Cell
528Figure 2. How Research on the Genetics of
Monogenic Forms of Familial Dementias of
the Alzheimer Type (***), Prototypic Unimodal
Progeroid Syndromes, Has Led to the Eluci-
dation of a Complex Web of Proteins that In-
teract with the Beta Amyloid Precursor Pro-
tein, including a Polymorphic Locus with a
Major Effect upon Common, “Sporadic,”
Late-Onset Forms of the Disease (APOE, **)
and Several Additional Loci for which Some
Evidence Exists to Support a Role for Ge-
netic Variants (*)
Standard abbreviations are utilized for the il-
lustrated proteins or protein derivatives of
interest. The photomicrograph insert is from
the cerebral cortex of a patient who died of
advanced dementia of the Alzeimer type. It
is stained with an antibody against β amloid
(Aβ). Note the extensive deposits of β amy-
loid in blood vessels as well as in brain pa-
renchyma. For further details on evidence for
the participation of network components in
the regulation of gene transcription, see Cao
and Sudhof (2004).Research on rare familial monogenic forms of the dis- L
Bease (“unimodal progeroid syndromes”) has thus led
the way for an understanding of mechanisms. The pos-
esibility remains, however, that the network depicted in
Figure 2 is only one of several important “nodes” in a t
oseries of interacting pathways modulating the develop-
ment of this type of CNS aging. Proteins involved in d
omitochondrial metabolism are likely to be among these
pathways (Coskun et al., 2004). A final point to make, l
oin the context of this review, is that the final word has
yet to be written on the possibility that at least some r
pforms of DAT may be more properly designated as
“segmental progeroid syndromes.” There is consider- g
oable evidence to support that assertion for the case of
the Down syndrome (Colvin et al., 2003; Martin, 1978). P
aFamilial Parkinson Disease and Variants—Multiple
Single-Gene Mutations, including MAPT (FTDP17); 2
aPARK1(a-synuclein); PARK2 (Parkin); PARK5
(UCH-L1); PARK6 (PINK1); PARK7 (DJ-1); n
iPARK3,4,8,9,10; NR4A2; LRRK2
Like DAT, the neurological picture of Parkinson disease p
f(PD) is becoming increasingly familiar to laymen as our
population swells with older cohorts. In the classical A
Aform of the disorder, one sees hand tremors while the
subject is resting (but not when pointing), muscular ri- c
agidity, extremely slow movements, postural instability
and disturbances of the autonomic nervous system. a
sThe typical clinical disease is associated with the char-
acteristic pathology in the substantia nigra and basal c
sganglia. In some forms of the disorder, there is more
extensive neurodegeneration, including cortical in- r
ovolvement and dementia.
Until the last decade or so, there was widespread h
nbelief that the disease had few, if any, significant ge-
netic components—a result of early twin studies and p
gexperience with the infamous influenza epidemic of
1918, which left large numbers of survivors with the dis- t
cease. Now we are faced with an explosion of candidate
loci associated with either autosomal-recessive or au- n
ptosomal-dominant modes of inheritance in subsets of
unusual families (see reviews by Bonifati et al., 2004; (e and Appel, 2004; Vila and Przedborski, 2004; Von
ohlen Und et al., 2004).
While, with the important exception of LRKK2 (Gilks
t al., 2005; Nichols et al., 2005; Di Fonzo et al., 2005),
hese pedigrees are collectively rare, their relevance for
ur understanding of pathogenetic mechanisms un-
erlying the more common “sporadic” forms of the dis-
rder is substantial. It is too early for a unifying molecu-
ar hypothesis to explain the pathogenesis of usual PD
n the basis of current information. For the case of the
ecessive forms of the disease, an emerging theme em-
hasizes a potential role of the PARK2 E3 ubiquitin li-
ase (Parkin), a putative antioxidant/chaperone effect
f the PARK7 DJ-1, and a putative kinase activity of the
ARK6 PINK1 in reconciling a role for both dopamine
nd mitochondrial metabolism (Shen and Cookson,
004; Martinat et al., 2004; Shendelman et al., 2004). An
ttractive generic hypothesis for a range of age-related
eurodegenerative disorders, including PD, DAT, Hunt-
ngton’s disease, Amyotrophic sclerosis, and familial
rion protein diseases, implicates a central role for mis-
olded, aggregated proteins (Forman et al., 2004).
ttenuated Familial Polyposis—APC; MYH
denocarcinomas of the colon exhibit exponential in-
reases in prevalence and incidence over the life span,
lthough with some decline in rates at very advanced




elated to the survival of unusually resistant genotypes
r to a cohort effect. The majority of the monogenic,
ighly penetrant genetic substrates for adenocarci-
oma of the colon also increase the risk for other neo-
lasms, thus ruling out their inclusion as unimodal pro-
eroid syndromes. It is important to point out, however,
hat hypomorphic (“leaky”) mutations or haploinsuffi-
iency may manifest only as relatively late-onset ade-
ocarcinoma of the colon. The best documented exam-
les of this to date are mutations at the APC locus
adenomatous polyposis coli) (Venesio et al., 2003),
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529which codes for a multifunctional tumor suppressor
gene involved with Wnt-mediated degradation of β ca-
tenin and with cytoskeletal dynamics that could modu-
late such functions as cell adhesion, migration, and mi-
tosis (Nathke, 2004). A valuable unifying hypothesis for
how heterozygous APC mutations lead to adenocarci-
nomas is that they change stem cell survival patterns
during early stages of the pathogenesis (Kim et al.,
2004).
MYH (the human homolog of the E. coli Mut Y gene)
is involved in base excision repair of DNA. Homozygous
or doubly heterozygous germline mutations at that lo-
cus, while expressed in all cells, may lead to attenuated
forms of colonic polyposis and adenocarcinoma of the
colon (Al-Tassan et al., 2002). The APC gene appears
to be a particularly vulnerable target for subsequent so-
matic mutations, for reasons that will require more re-
search.
Other Unimodal Progeroid Syndromes
It would be beyond the scope of this review to catalog
all of the known or suspected single-gene mutations
that have their major impacts upon specific common
geriatric disorders. A few examples include the ex-
tremely well-documented LDL mutations responsible
for premature coronary artery atherosclerosis (Brown
and Goldstein, 1974), the possibility that homoplastic
somatic mutations in mitochondrial DNA might explain
presbycusis (Fischel-Ghodsian, 2000; Dai et al., 2004),
the preliminary evidence for a major locus for suscep-
tibility to age-related macular degeneration (Iyengar et
al., 2004), and the ongoing linkage analysis to detect
major genes that modulate susceptibility to osteoporo-
sis (Shen et al., 2004).
Conclusions and Future Directions
We have seen that physicians and medical geneticists
have learned a great deal about spontaneous muta-
tions in our species (“experiments of nature”). Their
studies have begun to reveal aspects of the genetic
basis and pathogenetic mechanisms that underlie what
can be referred to as senescent phenotypes. We have
adopted a broad definition of such phenotypes, one
that relies upon the evolutionary biological theory of
aging. In brief, one might reasonably claim that any
phenotype, “public” or “private,” that escapes the force
of natural selection can be interpreted as a senescent
phenotype. Evolutionary theory predicts the essentially
complete failure of nature to have selected for or
against phenotypes that do not reach a level of expres-
sion until about age 40 (Charlesworth, 1994). While that
generalization has been reasonably challenged (Kaplan
and Robson, 2002; Lee, 2003; Carey, 2003), our ge-
nomes have been largely shaped by remote nature-nur-
ture transactions involving young, highly reproductive
members of age-structured populations.
We can imagine five stages of progress in our mis-
sion to learn about aging from these experiments of
nature. The first was the stage of careful phenotyping
coupled with the Mendelian analysis of pedigrees. That
was essentially the state of the art when this subject
was first reviewed in a comprehensive manner (Martin,
1978). The second and third stages were those of ge-
netic mapping and positional cloning, a few fruits ofwhich are given in the present review. The fourth will
involve the study of interacting proteins and the con-
struction of their networks. An example of progress
along these lines is given in Figure 2. We must await
advances in proteomics and systems analysis to com-
plete that phase of analysis. The fifth phase has hardly
begun. That will involve a paradigm shift in how medi-
cal geneticists and physicians spend most of their time.
Instead of dealing with very bad outcomes from experi-
ments of nature, they should increasingly be turning
their attention to exceptionally good outcomes. What
little progress we have seen has largely come from
studies of unusual longevities, but what is really re-
quired are longitudinal studies of rates of change of
multiple physiological functions, beginning in middle
age, for exceptionally large cohorts so that a genetic
analysis can discover alleles that underlie what could
be characterized as “elite” aging in one or more physio-
logical systems (Martin, 2002a). Such an initiative
should lead to the definition of important polymorphic
variants and should provide a firmer basis for the con-
cept of segmental aging.
Although much remains to be done, we can already
come to some tentative conclusions about some im-
portant general mechanisms of aging from the genetic
studies of progeroid syndromes. The first is that there
is evidence for multiple mechanisms of aging. The se-
cond is not at all surprising—namely that to age well,
one should have robust mechanisms for the mainte-
nance of genomic stability. The third is that oxidative
stress may be an important endogenous challenge to
the maintenance of genomic (and proteomic) stability
during aging. A fourth insight has come from the evi-
dence that replicative senescence can contribute to
senescent phenotypes and that telomeres and telome-
rase activities are major modulators of such pheno-
types in our species (Hofer et al., 2004). A fifth conclu-
sion is that aberrant protein folding and aggregation
may be responsible for many of the neurodegenerative
conditions that destroy the quality of life during the
later decades of the life course. Our collective goal
should be to discover the “Achilles heels” that we each
bear and to implement programs of diagnosis, preven-
tion, and therapy to trump our special vulnerabilities as
we age.
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